New

Multiple Sclerosis Therapeutics Market

2021

Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and Geography

Publication Month: Feb 2021 | Report Code: TIPRE00004057 | No. of Pages: 169 | Category: Pharmaceuticals | Status: Published

Market Insights

Multiple Sclerosis Therapeutics Market to Grow at a CAGR of 6.5% to reach US$ 39,223.59 Million from 2020 to 2027

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS.

The scope of the multiple sclerosis therapeutics market includes drug class, route of administration, distribution channel, and region. The market for multiple sclerosis therapeutics is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the multiple sclerosis therapeutics market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.

Lucrative Regions for Multiple Sclerosis Therapeutics Market

Lucrative Regions for Multiple Sclerosis Therapeutics Market

Get more information on this report :



Market Insights

Growing Prevalence of Multiple Sclerosis

Multiple sclerosis is a chronic disease that affects the brain, spinal cord, and optic nerves. The symptoms of multiple sclerosis include weakness, anxiety, abnormality of taste, reduced sensation, and blurred vision or vision loss. Some of the other signs are constipation, muscle stiffness, depression, thinking problems, and urinary problems.

Studies suggest that there is an increase in prevalence of multiple sclerosis across the globe. For instance, as per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were living with MS in the US. In 2010, estimated prevalence of the disease was 309 cases per 100,000 people, that is, there were 727,344 adults suffering from MS. Additionally, as per the Government of Canada, (2014–2015 estimates) over 77,000 Canadians are living with multiple sclerosis of which 3/4th are women.

Further, the Multiple Sclerosis Society estimated that about 110,000 people were suffering from the condition in the UK in 2018. It also mentioned that MS is more than twice prevalent in females than males. The number of new patients diagnosed per year is also increasing; it increased from 5,000 in 2017 to 6,700 in 2018.

Therefore, growing prevalence of multiple sclerosis is driving the multiple sclerosis therapeutics market.

Drug Class Based Insights

Based on multiple sclerosis therapeutics drug class, the multiple sclerosis therapeutics market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in MS treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.

Global Multiple Sclerosis Therapeutics Market, by Route of Administration – 2019 & 2027

Global Multiple Sclerosis Therapeutics Market, by Route of Administration – 2019 & 2027

Get more information on this report :


Route of Administration Based Insights

In terms of route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.

Distribution Channel Based Insights

Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID 19 has been established. Patients with severe health conditions, such as neurological diseases and others; are witnessing delays in such chronic disease treatment. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to open during the lock down. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the outbreak of COVID-19 pandemic.

Product launches and expansion strategies are commonly adopted by companies to expand their footprint worldwide and meet the growing demand. These strategies are commonly adopted by the market players in order to expand its product portfolio.


The market players operating in the

Multiple Sclerosis Therapeutics Market

adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

By Drug Class

  • Immunosuppressant
  • Immunomodulators

By Route of Administration

  • Injectable
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa
  • South America (SAM)
    • Brazil
    • Argentina
    • Rest of South America

Company Profiles

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD.
  • Biogen

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Multiple Sclerosis Therapeutics Market – By Drug Class

1.3.2 Global Multiple Sclerosis Therapeutics Market – By Route Of Administration

1.3.3 Global Multiple Sclerosis Therapeutics Market – By Distribution Channel

1.3.4 Global Multiple Sclerosis Therapeutics Market – By Geography

2. Multiple Sclerosis Therapeutics Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Multiple Sclerosis Therapeutics– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America – PEST Analysis

4.2.2 Europe – PEST Analysis

4.2.3 Asia Pacific – PEST Analysis

4.2.4 Middle East and Africa (MEA) – PEST Analysis

4.2.5 South and Central America (SCAM) – PEST Analysis

4.1 Expert Opinions

5. Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Prevalence of Multiple Sclerosis (MS)

5.1.2 Rising Funding for Multiple Sclerosis Research

5.2 Market Restraints

5.2.1 High Cost of Multiple Sclerosis Treatment

5.3 Market Opportunities

5.3.1 Increasing Awareness About Multiple Sclerosis

5.4 Future Trends

5.4.1 Development and Launch of Innovative Products

5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market – Global Analysis

6.1 Global Multiple Sclerosis Therapeutics Market Revenue Forecast And Analysis

6.2 Global Multiple Sclerosis Therapeutics Market, By Geography - Forecast And Analysis

6.3 Market Positioning of Key Players

7. Multiple Sclerosis Therapeutics Market Analysis – By Drug Class

7.1 Overview

7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

7.3 Immunosuppressant

7.3.1 Overview

7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

7.4 Immunomodulators

7.4.1 Overview

7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration

8.1 Overview

8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

8.3 Injectable

8.3.1 Overview

8.3.2 Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Oral

8.4.1 Overview

8.4.2 Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel

9.1 Overview

9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

9.3 Hospital Pharmacies

9.3.1 Overview

9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.4 Retail Pharmacies

9.4.1 Overview

9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.5 E-Commerce

9.5.1 Overview

9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis And Forecast To 2027 – Geographical Analysis

10.1 North America: Multiple Sclerosis Therapeutics Market

10.1.1 Overview

10.1.2 North America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.3 North America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.4 North America: Multiple Sclerosis Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

10.1.5 North America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

10.1.6 North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

10.1.7 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1 US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2 US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.7.3 US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.7.4 US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)

10.1.8 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.1 Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.2 Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.8.3 Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.8.4 Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018–2027 (USD Million)

10.1.9 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.1 Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.2 Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.1.9.3 Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.1.9.4 Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

10.2 Europe: Multiple Sclerosis Therapeutics Market

10.2.1 Overview

10.2.2 Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

10.2.3 Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.4 Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.5 Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.2.6 Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

10.2.7 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.7.1 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.7.2 Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.7.3 Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.7.4 Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.2.8 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.8.1 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.8.2 UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.8.3 UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.8.4 UK Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

10.2.9 France: Market – Revenue and Forecast to 2027 (USD Million)

10.2.9.1 France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.9.2 France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.9.3 France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.9.4 France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.2.10 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.10.1 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.10.2 Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.10.3 Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.10.4 Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.2.11 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.11.1 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.11.2 Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.11.3 Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.11.4 Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.2.12 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.12.1 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.2.12.2 Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

10.2.12.3 Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

10.2.12.4 Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

10.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027

10.3.1 Overview

10.3.2 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.4 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.3.5 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

10.3.6 Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)

10.3.7 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.7.1 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.7.2 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.7.3 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.3.7.4 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.8 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.8.1 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.8.2 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.8.3 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.3.8.4 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.9 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.9.1 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.9.2 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.9.3 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.3.9.4 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.10 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.10.1 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.10.2 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.10.3 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.10.4 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.11 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.11.1 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.3.11.2 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.3.11.3 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.3.11.4 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.3.12 Rest of Asia Pacific: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027

10.4.1 Overview

10.4.2 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.4.3 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.4.4 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.4.5 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

10.4.6 Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)

10.4.7 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.4.7.1 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.4.7.2 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.4.7.3 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.4.7.4 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.4.8 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027

10.4.8.1 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.4.8.2 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.4.8.3 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.4.8.4 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel US$ Mn)

10.4.9 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027

10.4.9.1 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

10.4.9.2 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

10.4.9.3 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)

10.4.9.4 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)

10.4.9.5 Rest of Middle East and Africa: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5 South and Central America: Multiple Sclerosis Therapeutics Market

10.5.1 Overview

10.5.2 South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.3 South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.5.4 South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.5.5 South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

10.5.6 South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

10.5.7 Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.7.1 Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.7.2 Brazil: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.5.7.3 Brazil: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.5.7.4 Brazil: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

10.5.8 Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.8.1 Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.8.2 Argentina: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.5.8.3 Argentina: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.5.8.4 Argentina: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

10.5.9 Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.9.1 Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

10.5.9.2 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018–2027 (USD Million)

10.5.9.3 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018–2027 (USD Million)

10.5.9.4 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018–2027 (USD Million)

11. Impact of COVID-19 Pandemic on Global Multiple Sclerosis Therapeutics Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment Of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

11.5 South & Central America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 Merck & Co., Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Novartis AG

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Sanofi

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bristol-Myers Squibb Company

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Horizon Therapeutics plc

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Takeda Pharmaceutical Company Limited

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 F. HOFFMANN-LA ROCHE LTD.

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Biogen

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms


LIST OF TABLES

Table 1. North America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 2. North America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 3. North America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 4. US Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 5. US Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 6. US Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 7. Canada Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 8. Canada Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 9. Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)

Table 10. Mexico Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 11. Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12. Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13. Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 14. Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 15. Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 16. Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 17. Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 18. Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 19. UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 20. UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 21. UK: Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million).

Table 22. France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 23. France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 24. France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 25. Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 26. Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 27. Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 28. Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 29. Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 30. Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 31. Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 32. Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 33. Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 34. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 35. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 36. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 37. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 38. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 39. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 40. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 41. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 42. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 43. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 44. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 45. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 46. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 47. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 48. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 49. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 51. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 55. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 56. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 57. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 58. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 59. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 60. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 61. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 62. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 63. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 64. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)

Table 65. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 66. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 70. South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 71. South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 72. South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 73. Brazil Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 74. Brazil Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 75. Brazil Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 76. Argentina Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 77. Argentina Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 78. Argentina Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 79. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 80. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 81. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 82. Organic Developments Done By Companies

Table 83. Inorganic Developments Done By Companies

Table 84. Glossary of Terms, Multiple sclerosis therapeutics Market


LIST OF FIGURES

Figure 1. Multiple Sclerosis Therapeutics Market Segmentation

Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Region

Figure 3. Multiple Sclerosis Therapeutics Market Overview

Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share

Figure 5. APAC to Show Significant Growth During Forecast Period

Figure 6. Multiple Sclerosis Therapeutics Market, by Geography (US$ Million)

Figure 7. Global Multiple Sclerosis Therapeutics Market – Leading Country Markets (US$ Million)

Figure 8. Global Multiple Sclerosis Therapeutics Market, Industry Landscape

Figure 9. North America PEST Analysis

Figure 10. Europe PEST Analysis

Figure 11. Asia Pacific PEST Analysis

Figure 12. Middle East and Africa (MEA) PEST Analysis

Figure 13. South and Central America (SCAM) PEST Analysis

Figure 14. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints

Figure 15. Global Multiple Sclerosis Therapeutics Market – Revenue Forecast And Analysis – 2019- 2027

Figure 16. Global Multiple Sclerosis Therapeutics Market – By Geography Forecast and Analysis – 2019- 2027

Figure 17. Market Positioning Of Key Players In Global Multiple Sclerosis Therapeutics Market

Figure 18. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

Figure 19. Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 20. Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 21. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

Figure 22. Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 23. Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 24. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

Figure 25. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 26. Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 27. E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 28. North America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 29. North America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 30. North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 31. US: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 32. Canada: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 33. Mexico: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 34. Europe: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 35. Europe Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 36. Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 37. Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 38. UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 39. France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 40. Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 41. Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 42. Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 43. Asia Pacific Multiple Sclerosis Therapeutics Market Overview, by Country (2019)

Figure 44. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 45. Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)

Figure 46. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 47. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 48. India Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)

Figure 49. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 52. Middle East & Africa Multiple Sclerosis Therapeutics Market Share Overview, By Country (2019)

Figure 53. Middle East And Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)

Figure 54. Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)

Figure 55. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)

Figure 56. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)

Figure 57. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)

Figure 59. South and Central America: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 60. South and Central America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 61. South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 62. Brazil: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 63. Argentina: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 64. Rest of South and Central America: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 65. Impact of COVID-19 Pandemic in North American Country Markets

Figure 66. Impact of COVID-19 Pandemic in European Country Markets

Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 68. Impact of COVID-19 Pandemic in Middle East & Africa Market

Figure 69. Impact of COVID-19 Pandemic in South & Central America Market

Figure 70. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Multiple Sclerosis Therapeutics Market

  1. Merck & Co., Inc.             
  2. Novartis AG         
  3. Bayer AG             
  4. Sanofi     
  5. Bristol-Myers Squibb Company     
  6. Horizon Therapeutics plc.              
  7. TEVA PHARMACEUTICAL INDUSTRIES LTD         
  8. Takeda Pharmaceutical Company Limited              
  9. F. HOFFMANN-LA ROCHE LTD.    
  10. Biogen
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Multiple Sclerosis Therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Multiple Sclerosis Therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00004057
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.